1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: Under our equity compensation plans, and subject to the specific approval of the Compensation Committee of our Board of Directors, grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise by allowing us to withhold shares of stock otherwise issuable to the grantee.
−Removed: During the three-month period ended March 31, 2021, we withheld 8,972 shares to satisfy grantee tax withholding obligations on restricted stock unit vesting events.
−Removed: Following is a summary of stock repurchases for the three-month period ended March 31, 2021 (in thousands, except share data):
+Added: Under our equity compensation plans, and subject to the approval of the Compensation Committee of our Board of Directors, employee grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise by allowing us to withhold shares of stock otherwise issuable to the grantee.
+Added: During the three-month period ended June 30, 2021, we withheld 1,093 shares to satisfy grantee tax withholding obligations on restricted stock award and restricted stock unit vesting events.
+Added: Following is a summary of stock repurchases for the three-month period ended June 30, 2021 (in thousands, except share data):
Total Number of
2 unchanged sentences
Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs(2)
−Removed: January 1 to 31, 2021
−Removed: February 1 to 28, 2021
−Removed: March 1 to 31, 2021
−Removed: On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program and $20.0 million reserved for open market repurchases.
−Removed: Through March 31, 2021, we had made no open market repurchases.
−Removed: On May 7, 2019, we entered into a previously-announced accelerated share repurchase agreement, or the ASR Agreement, to repurchase an aggregate of $30.0 million of common stock.
−Removed: During the second quarter of 2019, 451,694 shares were delivered to us, constituting the initial delivery of shares and representing 60% of the then estimated total number of shares expected to be repurchased under the ASR Agreement.
−Removed: On January 14, 2020, pursuant to the terms of the ASR Agreement, Morgan Stanley accelerated the final settlement date from February 2020, and the final number of shares and the average purchase price was determined.
−Removed: Based on the volume-weighted average price from the effective date of the ASR Agreement through January 14, 2020, less the applicable contractual discount, Morgan Stanley delivered 139,057 additional shares to us on January 17, 2020.
−Removed: In total, 590,751 shares were repurchased under the ASR Agreement at an average repurchase price of approximately $50.78.
−Removed: All shares were repurchased in accordance with the publicly announced program.
−Removed: 8,972 shares were withheld by us to satisfy grantee tax withholding obligations on restricted stock unit vesting events in February 2021.
−Removed: Exhibit No.  
−Removed: Form of Notice of Grant of Incentive Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc.
−Removed: 2017 Omnibus Incentive Plan
−Removed: Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc.
−Removed: 2017 Omnibus Incentive Plan
−Removed: Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc.
−Removed: 2017 Omnibus Incentive Plan
−Removed: Form of Notice of Grant of Deferred Stock Awards Units, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc.
−Removed: 2017 Omnibus Incentive Plan
+Added: April 1 to 30, 2021
+Added: May 1 to 31, 2021
+Added: June 1 to 30, 2021
+Added: 1,093 shares were withheld by us to satisfy grantee tax withholding obligations on restricted stock award and restricted stock unit vesting events in May 2021.
+Added: On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases.
+Added: No open market repurchases were made during the three-month period ended June 30, 2020.
+Added: Exhibit  
+Added: Anika Therapeutics, Inc.
+Added: 2017 Omnibus Incentive Plan (as amended effective June 16, 2021) (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed on June 22, 2021)
+Added: Anika Therapeutics, Inc.
+Added: 2021 Employee Stock Purchase Plan (adopted June 16, 2021) (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K filed on June 22, 2021)
Rule 13a-14(a)/15d-14(a) Certifications
6 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 as filed with the SEC on May 6, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:
−Removed: Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020 (unaudited)
−Removed: Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2021 and March 31, 2020 (unaudited)
−Removed: Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and March 31, 2020 (unaudited)
−Removed: Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and March 31, 2020 (unaudited)
+Added: The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 as filed with the SEC on August 5, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:
+Added: Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020 (unaudited)
+Added: Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2021 and June 30, 2020 (unaudited)
+Added: Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2021 and June 30, 2020 (unaudited)
+Added: Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and June 30, 2020 (unaudited)
Notes to Consolidated Financial Statements (unaudited)
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 
−Removed: Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(2).
−Removed: The omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
Filed herewith.
Furnished herewith.
+Added: †   
Management contract or compensatory plan or arrangement.
1 unchanged sentence
ANIKA THERAPEUTICS, INC.
+Added: August 5, 2021
/s/ MICHAEL LEVITZ
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.